In a research note released Tuesday, Goldman Sachs (nyse: GS - news - people ) biotech analyst May-Kin Ho wrote that positive results in this study could double the number of patients eligible for the therapy to 700, 000 people.
The biotechnology company got a taste of success when David Ho , a world-renowned AIDS researcher, used the ProteinChip to find a protein that may give some people resistance to the HIV virus.